Remove Biosimilars Remove Marketing Remove Webinar
article thumbnail

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Drug Channels

This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. During Friday's webinar, Ill share some updated thoughts on biosimilars and PBMs private label products. The Humira biosimilar market just took another step forwardbut remains far from its ideal state.

article thumbnail

The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars (rerun)

Drug Channels

This week, Im rerunning some popular posts while I prepare for Fridays live video webinar: PBM Industry Update: Trends, Challenges, and Whats Ahead. As youll see below, the combination of formulary exclusion and private labels is creating an increasingly confusing and crowded biosimilar marketplace. What do you think?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. I’ll be joined by special guest Antonio Ciaccia, CEO of 46brooklyn Research, and President of 3 Axis Advisors. Click here to see the original post from March 2025.

article thumbnail

Decades of LDT Tension Leads to an Epic Three-Hour Oral Argument

FDA Law Blog: Biosimilars

Judge Jordan asked ACLA for confirmation that he understood correctly that pre-market submission was the major burden for labs and that while pre-market submission compliance dates are still several years away, labs should be preparing now to meet FDAs pre-market expectations. ACLA, of course, confirmed that was true.

article thumbnail

Business Leaders Review - The Heart and Strategy Behind Altasciences' Marketing Evolution

Alta Sciences

MENU logo-altasciences EN - Main navigation Proactive Drug Development Solutions Compare Us Facilities About Us Resource Center Careers News & Events 30th Anniversary Celebration Contact Us Participate in a study Français Home Current: Business Leaders Review - The Heart and Strategy Behind Altasciences' Marketing Evolution Business Leaders (..)

article thumbnail

Drug Channels Update: Buy-and-Bill Market Trends (NEW Live Video Webinar)

Drug Channels

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The webinar will be 90 minutes to accommodate audience questions.

article thumbnail

The Biosimilar Boom and the Coming Humira Price War (Video)

Drug Channels

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilarsmarket share is approaching 80%. will face multiple biosimilar competitors. Prices are dropping while adoption accelerates. That’s when Humira, the best-selling drug in the U.S.,